TRK Inhibitors: Precision Medicine in Oncology : Episode 13

Genomic Profiling in Solid Tumor Malignancies: Challenges

April 19, 2019

Video

Transcript:

Related Videos

Sangeeta Goswami, MD, PhD, of The University of Texas MD Anderson Cancer Center

Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.

Andrew Ip, MD

Arya Amini, MD

Adrianna Masters, MD, PhD,

Chul Kim, MD, MPH

Andrew Ip, MD

In this final episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss a roadmap of artificial intelligence (AI) advances in the next 5 to 10 years.

In this eighth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, explain how artificial intelligence tools are being developed to match the right patient to the right drug on the right clinical trial.

In this seventh episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss how artificial intelligence tools may be utilized to improve wait time for treatment, to provide more time for provider-patient interactions, and more.

Related Content

FDA

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC

April 18th 2024

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021

Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center

Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC

Gordan on Growing the Infrastructure for In-House Genomic Testing

Gordan on Growing the Infrastructure for In-House Genomic Testing

October 14th 2021

Susan D. Klugman, MD, director, reproductive and medical genetics, program director, medical genetics and genomics, Montefiore Einstein; professor, obstetrics and gynecology and women’s health, Albert Einstein College of Medicine

Patient Insurance Status and Out-of-Pocket Costs Affect Genomic Testing Frequency

AI in cancer care

Clinicians Express Reservations Around Ethical Issues of AI in Cancer Care

Related Content

FDA

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC

April 18th 2024

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021

Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center

Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC

Gordan on Growing the Infrastructure for In-House Genomic Testing

Gordan on Growing the Infrastructure for In-House Genomic Testing

October 14th 2021

Susan D. Klugman, MD, director, reproductive and medical genetics, program director, medical genetics and genomics, Montefiore Einstein; professor, obstetrics and gynecology and women’s health, Albert Einstein College of Medicine

Patient Insurance Status and Out-of-Pocket Costs Affect Genomic Testing Frequency

AI in cancer care

Clinicians Express Reservations Around Ethical Issues of AI in Cancer Care

Latest Conference Coverage

Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer

As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.